Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure

被引:1
|
作者
Cohen-Solal, A
Rouzet, F
Berdeaux, A
Le Guludec, D
Abergel, E
Syrota, A
Merlet, P [1 ]
机构
[1] Univ Bichat, Ctr Hosp, Nucl Med Serv, F-75877 Paris, France
[2] Univ Hosp Beaujon, Dept Cardiol, Hop Paris, Clichy, France
[3] Univ Hosp Bichat, Dept Nucl Med, Paris, France
[4] Univ Hosp Henri Mondor, Dept Cardiol, Hop Paris, Creteil, France
[5] European Univ Hosp Georges Pompidou, Dept Cardiol, Hop Paris, Paris, France
[6] Commissariat Energie Atom, Dept Nucl Med Frederic Joliot, Orsay, France
关键词
uptake-1; catecholamines; congestive heart failure; carvedilol; MIBG;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Carvedilol is a P-blocking agent with antioxidant properties that has been shown to improve survival in chronic heart failure (CHF). Previous open-label studies have suggested that its use.may have positive effects on the abnormalities of cardiac sympathetic innervation integrity and functioning. The present study aimed to test the hypothesis that carvedilol exerts its beneficial effects on hemodynamics in parallel with an action on myocardial sympathetic activity and with its antioxidant property. Methods: A randomized, multicenter, double-blind, placebo-controlled study of carvedilol was conducted on 64 CHF patients. Patients underwent-before and after 6 mo of therapy with either carvedilol or placebo-measurements of cardiac sympathetic activity, circulating catecholamine level, and hemodynamic indices. Myocardial meta-(123)l-iodobenzylguanidine ((123)l-MIBG) uptake was used to assess the changes in myocardial sympathetic activity. The antioxidant properties of the plasma were assessed by measuring the percentage of nonhemolyzed erythrocytes and the volume of plasma capable of inhibiting 50% of hemolysis after an oxidative stress. Echographic left ventricular (LV) diameters, radionuclide LV ejection fraction (LVEF), and exercise cardiopulmonary capacity were measured to evaluate the hemodynamic response. Results: End-diastolic and end-systolic LV diameters decreased (both P < 0.05) and LVEF increased (P = 0.03) in the carvedilol group, whereas these parameters remained unchanged in the placebo group. Carvedilol did not alter the submaximal exercise cardiopulmonary capacity or the circulating catecholamine level. The beneficial hemodynamic effects in the carvedilol group were associated with an increase in myocardial (123)l-MIBG uptake as assessed by both planar and tomographic imaging (P < 0.01). Carvedilol had no detectable effect on antioxidant properties of the plasma. Conclusion: The benefits of carvedilol on resting hemodynamics appear to be associated with a partial recovery of cardiac adrenergic innervation functioning without detectable antioxidant effect in the plasma.
引用
收藏
页码:1796 / 1803
页数:8
相关论文
共 50 条
  • [1] Effect of carvedilol on myocardial perfusion in patients with chronic heart failure
    Kamilova, U.
    Jurayeva, S. H.
    Aliyeva, T.
    Kevorkov, A.
    Myasnik, B.
    [J]. CIRCULATION, 2008, 118 (12) : E231 - E232
  • [2] Effects of carvedilol in elderly patients with chronic heart failure
    Bristow, MR
    Gilbert, EM
    Packer, M
    Colucci, WS
    Lukas, MA
    Court, M
    Fowler, MB
    Cohn, JN
    [J]. CIRCULATION, 1997, 96 (08) : 3228 - 3228
  • [3] Differential effects of carvedilol and metoprolol on sympathetic regulation of peripheral vascular resistance in patients with chronic heart failure
    Hryniewicz, K
    Androne, AS
    Hudaihed, A
    Katz, SD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 148A - 148A
  • [4] Carvedilol in patients with chronic heart failure
    vonOlshausen, K
    Pop, T
    Berger, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (17): : 1318 - 1319
  • [5] Effects of bet-blocker therapy on the myocardial sympathetic Innervation in patients heart failure with preserved ejection fraction
    de Miranda, Sandra Marina
    Leao, Mauricio
    Jorge, Antonio Jose
    Martins, Wolney
    Amorim, Luana
    Messias, Leandro
    Mesquita, Evandro
    Mesquita, Claudio
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [6] Carvedilol in patients with chronic heart failure - Reply
    Packer, M
    Cohn, JN
    Colucci, WS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (17): : 1319 - 1320
  • [7] EFFECTS OF SWITCHING FROM CARVEDILOL TO BISOPROLOL IN PATIENTS WITH CHRONIC HEART FAILURE
    Taniguchi, Tatsunori
    Ichibori, Yasuhiro
    Kanzaki, Machiko Matsui
    Minamiguchi, Hitoshi
    Mizote, Isamu
    Ohtani, Tomohito
    Asano, Yoshihiro
    Sakata, Yasushi
    Komuro, Issei
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E885 - E885
  • [8] Effects of carvedilol on serum digoxin concentration for the patients with chronic heart failure
    Nomura, Akikazu
    Fujimoto, Testuya
    Machida, Maiko
    Takechi, Shigeru
    [J]. THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 536 - 536
  • [9] Effects of nelbivolol versus carvedilol in hypertensive patients with chronic heart failure
    Marazzi, Giuseppe
    Volterrani, Maurizio
    Caminiti, Giuseppe
    Massaro, Rosalba
    Iaia, Luigi
    Ciolli, Romina
    Mammi, Caterina
    Gatta, Lucia
    Rosano, Giuseppe M.
    [J]. CIRCULATION, 2007, 116 (16) : 551 - 551
  • [10] Effects of carvedilol therapy on exercise tolerance in patients with chronic heart failure
    Al-Nasser, F
    Yousufuddin, M
    Piepoli, M
    Al-Nozha, F
    Anker, S
    Coats, A
    Ponikowski, P
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 : 83 - 83